Four HCC cell lines with variable MET/MAPK/AKT pathway expression and activation levels were selected for testing specific MET-targeting CAR-T cell killing activity: MHCC97H cells have strong MET activation driven by METamp; JHH5 cells are known to have HGF autocrine-mediated MET activation; C3A cells have a MET expression level comparable to JHH5 cells but without MET activation; SNU398 cells do not express MET (Fig. 2A). The gene discussed is MET; the disease is hepatocellular carcinoma.